The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy
M Radosavljevic, D Svob Strac, J Jancic, J Samardzic - Genes, 2023 - mdpi.com
Pharmacotherapy for neuropsychiatric disorders, such as anxiety and depression, has been
characterized by significant inter-individual variability in drug response and the development …
characterized by significant inter-individual variability in drug response and the development …
Alzheimer's disease and drug delivery across the blood–brain barrier: approaches and challenges
Alzheimer's disease (AD) is a diverse disease with a complex pathophysiology. The
presence of extracellular β-amyloid deposition as neuritic plaques and intracellular …
presence of extracellular β-amyloid deposition as neuritic plaques and intracellular …
Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics
G Minegishi, Y Kobayashi, M Fujikura… - Pharmacology …, 2024 - Wiley Online Library
Abstract Human cytochrome P450 3A4 (CYP3A4) is a drug‐metabolizing enzyme that is
abundantly expressed in the liver and intestine. It is an important issue whether compounds …
abundantly expressed in the liver and intestine. It is an important issue whether compounds …
[HTML][HTML] Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility
Genetic factors influence medication response (pharmacogenetics), affecting the
pharmacodynamics and pharmacokinetics of many medicaments used in clinical care. The …
pharmacodynamics and pharmacokinetics of many medicaments used in clinical care. The …